Cambridge, Mass., November 1, 2016 - Decibel Therapeutics, a company focused on discovering and developing new therapies to protect, repair and restore hearing, today announced the formation of the company’s scientific advisory board comprised of preeminent hearing loss experts and leaders in neuroscience, genetics and drug discovery. Decibel’s scientific advisory board will provide valuable scientific insight and advice as the company seeks to discover, develop and deliver novel therapies to better the lives of those living with impaired hearing.
“We are pleased to welcome these world-renowned members of the bio-medical community to Decibel’s scientific advisory board,” said Steven Holtzman, president and chief executive officer of Decibel Therapeutics. “These advisors will work closely with Decibel’s leadership team and will be an integral part of the company’s strategy as we pursue our mission to protect, repair and restore hearing.”
Decibel’s scientific advisory board comprises:
· M. Charles Liberman, Ph.D., co-founder of Decibel Therapeutics; Schuknecht Professor of Otology and Laryngology, Harvard Medical School; director of the Eaton-Peabody Laboratory, Massachusetts Eye and Ear
· Gabriel Corfas, Ph.D., co-founder of Decibel Therapeutics; director, Kresge Hearing Research Institute; professor and associate chair for research, Department of Otolaryngology—Head and Neck Surgery, University of Michigan
· Albert Edge, Ph.D., co-founder of Decibel Therapeutics; professor, Otology and Laryngology, Harvard Medical School; director, Tillotson Cell Biology Unit, Massachusetts Eye and Ear
· Ulrich Müller, Ph.D., co-founder of Decibel Therapeutics; Bloomberg Distinguished Professor and director of Developmental Neuroscience, John Hopkins University
· Peter Barr-Gillespie, Ph.D., associate vice president for basic research, Oregon Health & Sciences University; professor, department of otolaryngology—Head and Neck Surgery, Oregon Health & Sciences University; senior scientist, Vollum Institute
· Alan Cheng, M.D., associate professor, department of Otolaryngology, Stanford University School of Medicine; pediatric otolaryngologist, Stanford Health Care
· Hans Clevers, M.D., Ph.D., director of research, Princess Maxima Center for Pediatric Oncology; professor of molecular genetics, Hubrecht Institute (Netherlands)
· Bernd Fritzsch, Ph.D., comparative molecular neuroembryologist, University of Iowa; co-director, Aging Mind and Brain Initiative (AMBI); director, Center of Aging (CoA)
· David Ginty, Ph.D., Edward R. and Anne G. Lefler Professor of Neurobiology, Harvard Medical School; investigator, Howard Hughes Medical Institute
· Michael Greenberg, Ph.D., department chair and Nathan Marsh Pusey Professor of Neurobiology, Harvard Medical School
· Stuart L. Schreiber, Ph.D., co-founder, Broad Institute; director, Center for the Science of Therapeutics
About Decibel Therapeutics
Decibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic discovery, development, and delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of impaired hearing and develop breakthrough therapies. Founded by the world’s preeminent experts in impaired hearing, Decibel Therapeutics was launched in 2015 by Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit www.decibeltx.com.
